Exchange: NASDAQ·Updated 07:30 PM EDT
Latest Earnings Results: Q2 '26

Reported: Aug 07

Estimated EPS

-$0.06

Reported EPS

-$0.12

Surprise

-111.76%

Estimated Rev

$26.49M

Reported Rev

$29.1M

Surprise

+9.87%

• Reported GAAP EPS of -$0.12 • Reported revenue of $29.11M up 8.72% YoY • Gyre Therapeutics, Inc. affirmed its full year 2026 revenue guidance of $100.5 million to $111.0 million, reflecting the company's outlook for its commercial-stage biopharmaceutical product portfolio and development initiatives.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '26
-$0.12
--
--
N/A
Q2 '26
-$0.06
-$0.12
-111.76%
MISSED
Q1 '26
-$0.07
-$0.10
-36.36%
MISSED
Q4 '25
$0.06
-$0.02
-135.29%
MISSED
Q3 '25
$0.03
$0.03
12.50%
BEAT

Advertisement|Remove ads.